Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 2;3(6):e000406.
doi: 10.1136/esmoopen-2018-000406. eCollection 2018.

Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature

Jan Norum  1 , Carsten Nieder  2
Affiliations

Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature

Jan Norum et al. ESMO Open. .

Abstract

Background: Programmed death ligand 1 (PD-L1) targeting immunotherapies, as pembrolizumab and nivolumab, have significantly improved outcome in patients with non-small cell lung cancer (NSCLC). Tobacco smoking is the number one risk factor for lung cancer and is linked to 80%-90% of these cancers. Smoking during cancer therapy may influence on radiotherapy and chemotherapy outcome. We aimed to review the knowledge in immunotherapy.

Patients and methods: A systematic review was done. We searched for documents and articles published in English language and registered in Cochrane Library, National Health Service (NHS) Centre for Reviews and Dissemination (CRD), Embase or Medline. The search terms were (A) (Lung cancer or NSCLC) with (pembrolizumab or nivolumab) with PD-L1 with (tobacco or smoking) and (B) Lung Neoplasms and Immunotherapy and (smoking cessation or patient compliance). 68 papers were detected and two more were added during review process (references) and six based on information from the manufacturers.

Results: Nine papers were selected. High PD-L1 expression (≥50%) was correlated with current/ever smoking history in three studies. Six studies revealed a higher overall response rate (ORR) among current/former smokers. The ORR was generally (six studies) better among the current/former smoker group. So also when tumours had a molecular 'smoking signature' (one study). This was probably due to a higher mutational burden. In two studies, minor or no difference was revealed.One study (KEYNOTE-024) compared former and current smokers, and documented pembrolizumab being more effective among former smokers than current smokers.

Conclusions: Tobacco smoking patients with NSCLC generally have a higher PD-L1 tumour proportion score and experience a better ORR of immunotherapy than no smokers. There is little evidence on the effect of smoking during immunotherapy, but one study (KEYNOTE-024) may indicate survival gains of smoking cessation.

Keywords: PD-L1; cessation; immunotherapy; lung cancer; smoking; tobacco.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
The selection process.
See this image and copyright information in PMC

References

    1. Brawley OW. Avoidable cancer deaths globally. CA Cancer J Clin 2011;61:67–8. 10.3322/caac.20108 - DOI - PubMed
    1. Bates SE. Quit early, quit often. Clin Cancer Res 2015;21:2212 10.1158/1078-0432.CCR-14-2749 - DOI - PubMed
    1. Hirsch FR, Scagliotti GV, Mulshine JL, et al. . Lung cancer: current therapies and new targeted treatments. Lancet 2017;389:299–311. 10.1016/S0140-6736(16)30958-8 - DOI - PubMed
    1. Arteaga CL, Adamson PC, Engelman JA, et al. . AACR Cancer progress report 2014. Clin Cancer Res 2014;20: S1–112. 10.1158/1078-0432.CCR-14-2123 - DOI - PMC - PubMed
    1. Norway S. Smoking habits in Norway. Oslo: Statistics Norway, 2018.